Immunotherapeutic Targets and Therapy for Renal Cell Carcinoma.
anti-CTLA-4
anti-PD-1
biomarkers
immunotherapy
metastatic renal cell carcinoma
targeted therapy
Journal
ImmunoTargets and therapy
ISSN: 2253-1556
Titre abrégé: Immunotargets Ther
Pays: New Zealand
ID NLM: 101606565
Informations de publication
Date de publication:
2020
2020
Historique:
received:
04
09
2020
accepted:
24
10
2020
entrez:
23
11
2020
pubmed:
24
11
2020
medline:
24
11
2020
Statut:
epublish
Résumé
Over the last 20 years, different therapies have been considered as the mainstay for the treatment of patients with metastatic renal cell carcinoma (mRCC). Since angiogenesis is a key mechanism in the pathogenesis of renal carcinoma, research is still focusing on the inhibition of new vessel growth through the development of novel and potent tyrosine kinase inhibitors (TKIs), such as cabozantinib. On the other hand, a new therapeutic scenario has opened up in the forefront with immunotherapy. Immune checkpoint inhibitors (ICIs), which already represent a standard treatment option in pretreated mRCC patients, are revolutionizing the frontline therapeutic armamentarium of mRCC. Upfront combination immunotherapy as well as combinations of immunotherapy with targeted agents showed to significantly improved outcomes of mRCC patients compared to single-agent TKIs. ICIs are associated with long-lasting responses. Nonetheless, several unmet needs remain, as a small proportion of patients shows primary refractoriness to immunotherapy. Multiple treatment strategies combining different mechanisms of action or targeting immune escape pathways are emerging with the aim to improve response rates and survival outcomes. This review summarizes current immunotherapeutic targets and therapies approved for mRCC, while examining mechanisms of resistance and future directions, with the aim to address novel treatment strategies and help in improving the management of this tumor.
Identifiants
pubmed: 33224904
doi: 10.2147/ITT.S240889
pii: 240889
pmc: PMC7671463
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
273-288Informations de copyright
© 2020 Sepe et al.
Déclaration de conflit d'intérêts
Dr. Giuseppe Procopio received honoraria from Ipsen, Pfizer, BMS, AstraZeneca, and Janssen outside the submitted work, reports consultancy or advisory roles for Bayer, BMS, Janssen, Ipsen, MSD, Pfizer, and Novartis, and reports no other potential conflicts of interest for this work. The remaining authors report no conflicts of interest in this work.
Références
Front Oncol. 2019 Mar 01;9:117
pubmed: 30881919
Sci Transl Med. 2015 Mar 18;7(279):279ra41
pubmed: 25787767
Melanoma Res. 2005 Oct;15(5):417-25
pubmed: 16179869
Cancer. 2010 Sep 15;116(18):4256-65
pubmed: 20549832
Trends Immunol. 2015 Dec;36(12):763-777
pubmed: 26572555
J Immunother Cancer. 2019 Apr 3;7(1):99
pubmed: 30944023
Genome Biol. 2016 Nov 17;17(1):231
pubmed: 27855702
Clin Epigenetics. 2017 May 30;9:59
pubmed: 28572863
Clin Cancer Res. 2015 Apr 1;21(7):1639-51
pubmed: 25589619
N Engl J Med. 2015 Nov 5;373(19):1814-23
pubmed: 26406150
Science. 2018 Feb 16;359(6377):801-806
pubmed: 29301960
Immune Netw. 2015 Jun;15(3):121-4
pubmed: 26140043
Mol Cancer Ther. 2014 Apr;13(4):890-901
pubmed: 24523301
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Rev Urol. 2014;16(3):118-21
pubmed: 25337041
J Cancer. 2013;4(1):3-11
pubmed: 23386900
J Clin Oncol. 2010 Feb 20;28(6):1061-8
pubmed: 20100962
Semin Oncol. 1986 Jun;13(2):207-17
pubmed: 2424089
Oncotarget. 2016 Jun 7;7(23):34341-55
pubmed: 27145284
Lancet. 2007 Dec 22;370(9605):2103-11
pubmed: 18156031
J Oncol Pract. 2018 Apr;14(4):247-249
pubmed: 29517954
Cancer Res. 2015 Jun 1;75(11):2139-45
pubmed: 25977340
Cancer Sci. 2019 May;110(5):1564-1572
pubmed: 30861269
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Nat Rev Urol. 2016 Jul;13(7):420-31
pubmed: 27324121
J Dermatol Sci. 2010 Jul;59(1):1-6
pubmed: 20570112
Blood. 2003 Jun 15;101(12):4878-86
pubmed: 12586633
Eur J Cancer. 2018 May;94:115-125
pubmed: 29550566
J Clin Oncol. 2010 May 1;28(13):2144-50
pubmed: 20368553
Oncoimmunology. 2016 Dec 23;6(1):e1261779
pubmed: 28197389
J Clin Oncol. 1995 Mar;13(3):688-96
pubmed: 7884429
Trends Immunol. 2013 Mar;34(3):137-43
pubmed: 23103127
Lancet. 2019 Jun 15;393(10189):2404-2415
pubmed: 31079938
Nat Rev Urol. 2019 Sep;16(9):539-552
pubmed: 31278395
Cancer Cell Microenviron. 2015;2(1):
pubmed: 26005708
Nat Rev Immunol. 2009 Mar;9(3):162-74
pubmed: 19197294
Eur J Cancer. 2016 Feb;54:139-148
pubmed: 26765102
J Urol. 2003 Aug;170(2 Pt 1):588-92
pubmed: 12853836
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
J Clin Med. 2020 Mar 28;9(4):
pubmed: 32231117
Cell. 2017 May 4;169(4):736-749.e18
pubmed: 28475899
Ann Oncol. 2020 Aug;31(8):1030-1039
pubmed: 32339648
Nature. 2018 Feb 22;554(7693):538-543
pubmed: 29443964
Anal Cell Pathol (Amst). 2016;2016:9307549
pubmed: 27807511
J Exp Med. 2014 May 5;211(5):781-90
pubmed: 24778419
Nat Med. 2018 May;24(5):556-562
pubmed: 29736026
N Engl J Med. 2007 Jan 11;356(2):115-24
pubmed: 17215529
Front Oncol. 2014 Apr 14;4:64
pubmed: 24782981
Nat Commun. 2017 Feb 24;8:14607
pubmed: 28233863
J Immunother. 2007 Nov-Dec;30(8):825-30
pubmed: 18049334
Cancer Discov. 2012 Oct;2(10):881-98
pubmed: 23009760
Int J Mol Sci. 2019 Aug 30;20(17):
pubmed: 31480348
J Exp Med. 2006 Jul 10;203(7):1651-6
pubmed: 16801397
N Engl J Med. 1998 Apr 30;338(18):1265-71
pubmed: 9562580
J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):S272-83
pubmed: 20061007
Front Immunol. 2018 Jun 11;9:1310
pubmed: 29942309
J Clin Oncol. 2005 Feb 10;23(5):1028-43
pubmed: 15534359
Cancer Discov. 2015 Jul;5(7):752-67
pubmed: 26069190
Science. 2015 Apr 3;348(6230):69-74
pubmed: 25838375
J Clin Oncol. 2018 Oct 29;:JCO2018792648
pubmed: 30372396
Immunity. 2017 Feb 21;46(2):197-204
pubmed: 28228279
Cancer Discov. 2020 Aug;10(8):1158-1173
pubmed: 32439653
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Nat Commun. 2016 Feb 17;7:10501
pubmed: 26883990
J Clin Oncol. 2010 May 1;28(13):2137-43
pubmed: 20368558
J Clin Oncol. 2018 Jun 10;36(17):1685-1694
pubmed: 29489427
J Immunol. 1998 Feb 1;160(3):1224-32
pubmed: 9570538
Oncologist. 2019 Nov;24(11):1497-1501
pubmed: 31399500
Front Oncol. 2018 Mar 28;8:86
pubmed: 29644214
J Exp Med. 2013 Jul 1;210(7):1389-402
pubmed: 23752227
Clin Genitourin Cancer. 2021 Oct;19(5):434-446
pubmed: 34006498
Annu Rev Immunol. 2004;22:329-60
pubmed: 15032581
J Clin Oncol. 2017 Dec 1;35(34):3851-3858
pubmed: 28678668
Prostate Cancer Prostatic Dis. 2015 Dec;18(4):325-32
pubmed: 26260996
Cancer Cell. 2015 Apr 13;27(4):439-49
pubmed: 25858803
Nat Med. 2018 Jun;24(6):749-757
pubmed: 29867230
N Engl J Med. 2007 Jan 11;356(2):125-34
pubmed: 17215530
Immunity. 2008 Sep 19;29(3):362-71
pubmed: 18799144
Lancet Oncol. 2019 Oct;20(10):1370-1385
pubmed: 31427204
Expert Opin Biol Ther. 2019 Nov;19(11):1107-1110
pubmed: 31369337
Lancet. 2016 Feb 27;387(10021):894-906
pubmed: 26318520
Front Oncol. 2019 Oct 15;9:1073
pubmed: 31681606
N Engl J Med. 2016 Sep 1;375(9):819-29
pubmed: 27433843
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308